Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 229 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elderly Immune Senescence Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Lactoferrin, a Dietary Supplement, vs. Placebo on Respiratory Tract Infections

NCT04713735
View directory record Official record
Conditions
Immune Health
Interventions
Control: Placebo, bovine lactoferrin supplement
Dietary Supplement
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)

NCT04016662
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with HCL or PLGS
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
65 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
4
States / cities
Orlando, Florida • Rochester, Minnesota • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

NCT02709538
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

NCT00809757
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol, Levalbuterol UDV TID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 24, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional

Allo CART-19 Protocol

NCT01551043
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

R-CHOP + GM-CSF for Previously Untreated LCL in Elderly

NCT00582725
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
R-CHOP+GM-CSF
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma

NCT00003278
View directory record Official record
Conditions
Lymphoma
Interventions
dexamethasone, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
13
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

NCT00192322
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T 10^7, CAIVT 10^5, Placebo, TIV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
2
States / cities
New Port Richey, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine

NCT04866576
View directory record Official record
Conditions
Cognitive Change, Inflammation, Immune Response
Interventions
Q CAN PLUS, Placebo
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
65 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 24, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional

Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas

NCT00003113
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, lomustine, procarbazine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2011 · Synced Sep 24, 2026, 1:10 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Measurement of FeNO in Young Children With the NIOX VERO

NCT02661984
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Aerocrine AB
Industry
Eligibility
4 Years to 6 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Gilbert, Arizona • Blue Bell, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Geriatric Communication Skills Training Program for Oncology Clinicians

NCT03530969
View directory record Official record
Conditions
GI Cancer, Lymphoma, GU Cancer, Bone Marrow Transplant
Interventions
Self-Efficacy Assessment, UCLA Geriatrics Attitudes Scale, Course Evaluations, The Consultation and Relational Empathy (CARE) questionnaire, Consumer Assessment of Health Care Providers and Systems Program (CAHPS), Patient activation measure (PAM) scale
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 24, 2026, 1:10 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 24, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination

NCT01153906
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 25 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

NCT00377585
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, adjuvanted influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
10
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 24, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Rituximab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Berkeley, California • La Jolla, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
View directory record Official record
Conditions
Asthma
Interventions
FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 24, 2026, 1:10 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

NCT07406360
View directory record Official record
Conditions
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNS, MMRV
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Months to 6 Years
Enrollment
1,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Walnut Creek, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

NCT00963235
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine, Blood draw
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 24, 2026, 1:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

NCT00619801
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years to 6 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 24, 2026, 1:10 PM EDT